Abstract:TLK and ASF1 levels are elevated in AML patient samples across genetic subtypes and upregulated by IL-1β-mediated inflammatory stress. Targeting TLK2 or ASF1B suppresses IL-1b-driven AML progression through regulation of cell cycle and DNA damage responses in AML. Identifying and targeting microenvironment-driven pathways that are active across acute myeloid leukemia (AML) genetic subtypes should allow the development of more broadly effective therapies. The pro-inflammatory cytokine IL-1 is abundant in the AML microenvironment and promotes leukemic growth. Through RNA-sequencing analysis, we identify that IL-1 upregulated ASF1B (anti-silencing function-1B), a histone chaperone, in AML progenitors compared to healthy progenitors. ASF1B, along with its paralogous protein ASF1A recruits H3-H4 histones onto the replication fork during S-phase, a process regulated by tousled-like kinase 1 and 2 (TLKs). While ASF1s and TLKs are known to be overexpressed in multiple solid tumors and associated with poor prognosis, their functional roles in hematopoiesis and inflammation-driven leukemia remain unexplored. In this study, we identify that ASF1s and TLKs are over-expressed in multiple genetic subtypes of AML. We demonstrate that depletion of ASF1s significantly reduces leukemic cell growth in both in vitro and in vivo models using human cells. Using a murine model we show that overexpression of ASF1B accelerates leukemia progression. Moreover, Asf1b or Tlk2 deletion delayed leukemia progression while these proteins are dispensable for normal hematopoiesis. Through proteomics and phosphoproteomics analyses, we uncover that the TLK-ASF1 pathway promotes leukemogenesis by impacting the cell cycle and DNA damage pathways. Collectively, our findings identify the TLK1-ASF1 pathway as a novel mediator of inflammatory signaling and a promising therapeutic target for AML treatment across diverse genetic subtypes. Selective inhibition of this pathway offers potential opportunities to intervene effectively, address intratumoral heterogeneity, and ultimately improve clinical outcomes in AML.

FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia

Mir-196B Directly Targets Both HOXA9/MEIS1 Oncogenes and FAS Tumour Suppressor in MLL-rearranged Leukaemia.

Alox5 Exhibits Anti-Tumor and Drug-Sensitizing Effects in Mll-Rearranged Leukemia

3023 – ELUCIDATING THE MECHANISMS OF LEUKEMOGENESIS DRIVEN BY FBXO11 LOSS

Loss of FBXO11 function establishes a stem cell program in acute myeloid leukemia through dysregulation of mitochondrial LONP1

Long Non-Coding RNA Zinc Finger Antisense 1 Functions As an Oncogene in Acute Promyelocytic Leukemia Cells.

Leukemia Stem Cells: the Root of Chronic Myeloid Leukemia

Targeting UHRF1-SAP30-MXD4 axis for leukemia initiating cell eradication in myeloid leukemia

The Non-Cell-autonomous Function of ID1 Promotes AML Progression Via ANGPTL7 from the Microenvironment.

Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development

CBX2 shapes chromatin accessibility promoting AML via p38 MAPK signaling pathway

Phase separation-competent FBL promotes early pre-rRNA processing and translation in acute myeloid leukaemia

HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis

A small molecule BCL6 inhibitor as chemosensitizers in acute myeloid leukemia

A PRC2-Kdm5b axis sustains tumorigenicity of acute myeloid leukemia

The TLK-ASF1 histone chaperone pathway plays a critical role in IL-1b-mediated AML progression

BACH2-mediated CD28 and CD40LG axes contribute to pathogenesis and progression of T-cell lymphoblastic leukemia

Loss of RNA-binding protein CELF2 promotes acute leukemia development via FAT10-mTORC1

ZFP36L2, a Novel AML1 Target Gene, Induces AML Cells Apoptosis and Inhibits Cell Proliferation

Bahcc1 is critical for the aberrant epigenetic program in a mouse model of MLL-ENL- mediated leukemia

RNA-binding Proteins As Drivers of AML and Novel Therapeutic Targets.